Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Commerce Bank

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 15.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 2,016 shares of the biotechnology company’s stock after purchasing an additional 274 shares during the period. Commerce Bank’s holdings in Sarepta Therapeutics were worth $252,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in SRPT. Tidal Investments LLC increased its holdings in Sarepta Therapeutics by 8.5% in the 1st quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 228 shares during the last quarter. Comerica Bank boosted its position in Sarepta Therapeutics by 489.4% in the 1st quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock valued at $432,000 after buying an additional 2,770 shares during the period. New Covenant Trust Company N.A. purchased a new position in Sarepta Therapeutics in the 1st quarter valued at approximately $32,000. Farallon Capital Management LLC boosted its position in Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares during the period. Finally, Cetera Investment Advisers boosted its position in Sarepta Therapeutics by 27.6% in the 1st quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company’s stock valued at $1,552,000 after buying an additional 2,590 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Trading Up 5.7 %

NASDAQ SRPT opened at $137.94 on Thursday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $13.18 billion, a PE ratio of 104.40 and a beta of 0.81. Sarepta Therapeutics, Inc. has a one year low of $78.67 and a one year high of $173.25. The firm’s fifty day moving average is $121.90 and its two-hundred day moving average is $131.39.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SRPT shares. UBS Group raised their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. HC Wainwright assumed coverage on shares of Sarepta Therapeutics in a research report on Monday. They set a “sell” rating and a $80.00 price objective for the company. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Citigroup decreased their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.